ATE291582T1 - Verfahren zur synthese von nukleosidanaloga - Google Patents

Verfahren zur synthese von nukleosidanaloga

Info

Publication number
ATE291582T1
ATE291582T1 AT00303892T AT00303892T ATE291582T1 AT E291582 T1 ATE291582 T1 AT E291582T1 AT 00303892 T AT00303892 T AT 00303892T AT 00303892 T AT00303892 T AT 00303892T AT E291582 T1 ATE291582 T1 AT E291582T1
Authority
AT
Austria
Prior art keywords
synthesis
nucleoside analogs
nucleoside
analogs
Prior art date
Application number
AT00303892T
Other languages
German (de)
English (en)
Inventor
Robert William Scott
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE291582T1 publication Critical patent/ATE291582T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00303892T 1999-05-11 2000-05-09 Verfahren zur synthese von nukleosidanaloga ATE291582T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13365199P 1999-05-11 1999-05-11

Publications (1)

Publication Number Publication Date
ATE291582T1 true ATE291582T1 (de) 2005-04-15

Family

ID=22459680

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00303892T ATE291582T1 (de) 1999-05-11 2000-05-09 Verfahren zur synthese von nukleosidanaloga

Country Status (22)

Country Link
US (1) US6271370B1 (enEXAMPLES)
EP (1) EP1052264B1 (enEXAMPLES)
JP (1) JP2001011092A (enEXAMPLES)
KR (1) KR100403900B1 (enEXAMPLES)
CN (1) CN1275575A (enEXAMPLES)
AR (1) AR028991A1 (enEXAMPLES)
AT (1) ATE291582T1 (enEXAMPLES)
AU (1) AU3401100A (enEXAMPLES)
BR (1) BR0002089A (enEXAMPLES)
CA (1) CA2307951A1 (enEXAMPLES)
CZ (1) CZ20001710A3 (enEXAMPLES)
DE (1) DE60018833D1 (enEXAMPLES)
HU (1) HUP0001843A3 (enEXAMPLES)
ID (1) ID25992A (enEXAMPLES)
IL (1) IL136027A0 (enEXAMPLES)
IN (1) IN186850B (enEXAMPLES)
MX (1) MXPA00004532A (enEXAMPLES)
PL (1) PL340109A1 (enEXAMPLES)
RU (1) RU2200738C2 (enEXAMPLES)
TR (1) TR200001340A2 (enEXAMPLES)
YU (1) YU25500A (enEXAMPLES)
ZA (1) ZA200002263B (enEXAMPLES)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
NZ552927A (en) * 2004-07-21 2010-05-28 Pharmasset Inc Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
JP5138585B2 (ja) * 2005-05-05 2013-02-06 アーディア・バイオサイエンシーズ・インコーポレイテッド Ｈｉｖの処置のための非ヌクレオシド逆転写酵素インヒビターとしてのジアリル−プリン、−アザプリンおよび−デアザプリン
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
EP1924553A1 (en) 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
JP5006330B2 (ja) 2005-10-21 2012-08-22 ノバルティス アーゲー Ｉｌ１３に対するヒト抗体および治療的使用
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
RU2009120389A (ru) 2006-10-30 2010-12-10 Новартис АГ (CH) Гетероциклические соединения в качестве противовоспалительных агентов
WO2009079412A2 (en) 2007-12-14 2009-06-25 Ardea Biosciences Inc. Reverse transcriptase inhibitors
HRP20110414T1 (hr) 2007-12-14 2011-08-31 Pulmagen Therapeutics (Asthma) Limited Indoli i njihova uporaba u liječenju
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
WO2010088335A1 (en) 2009-01-29 2010-08-05 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions
MX2011008496A (es) 2009-02-17 2011-11-18 Chiesi Farma Spa Derivados de triazolopiridina como inhibidores de proteinas cinasas activadas por mitogeno p38 (map).
US8927513B2 (en) * 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
CN105078978A (zh) 2009-08-17 2015-11-25 因特利凯公司 杂环化合物及其用途
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
CA2828219A1 (en) 2011-02-25 2012-08-30 Irm Llc Pyrazolo [1,5-a] pyridines as trk inhibitors
AU2012310168B2 (en) 2011-09-15 2015-07-16 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
CN104363914A (zh) 2011-11-23 2015-02-18 因特利凯有限责任公司 使用mTOR抑制剂的增强的治疗方案
US9458154B2 (en) 2011-12-09 2016-10-04 Chiesi Farmaceutici S.P.A. Kinase inhibitors
ME02624B (me) 2011-12-09 2017-06-20 Chiesi Farm Spa Inhibitori kinaze
CN103974953B (zh) 2011-12-09 2016-06-29 奇斯药制品公司 激酶抑制剂
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
JP6189948B2 (ja) 2012-06-29 2017-08-30 ファイザー・インク ＬＲＲＫ２阻害薬としての新規な４−（置換アミノ）−７Ｈ−ピロロ［２，３−ｄ］ピリミジン
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
AR096532A1 (es) 2013-06-06 2016-01-13 Chiesi Farm Spa Inhibidores de quinasa
AU2014317600A1 (en) 2013-09-05 2016-03-03 F.Hoffmann-La Roche Ag Triazolopyridine compounds, compositions and methods of use thereof
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
ES2663622T3 (es) 2013-12-17 2018-04-16 Pfizer Inc. Novedosas 1H-pirrolo[2,3-b]piridinas 3,4-disustituidas y 7H-pirrolo[2,3-c]piridacinas 4,5-disustituidas como inhibidores de LRRK2
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
EP3265464A1 (en) 2015-03-04 2018-01-10 F. Hoffmann-La Roche AG Triazolopyridine compounds and methods of use thereof
WO2017046675A1 (en) 2015-09-14 2017-03-23 Pfizer Inc. Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
WO2017108736A1 (en) 2015-12-23 2017-06-29 Chiesi Farmaceutici S.P.A. N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
MA44131A (fr) 2015-12-23 2021-05-26 Chiesi Farm Spa Dérivés de 1-(3-tert-butyl-2h-pyrazol-5-yl or 5-tert-butyl-isoxaol-3-yl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalenyl) urée et leur utlisation en tant qu'inhibiteurs de p38 mapk
AR107165A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa Inhibidores de quinasa
EP3452464B1 (en) 2016-05-05 2021-12-15 F. Hoffmann-La Roche AG Pyrazole derivatives, compositions and therapeutic use thereof
AU2017324281A1 (en) 2016-09-06 2019-03-21 F. Hoffmann-La Roche Ag 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-A]pyridinyl compounds, compositions and methods of use thereof
BR112019013287A2 (pt) 2016-12-29 2019-12-24 Hoffmann La Roche compostos de pirazolopirimidina e métodos de uso dos mesmos
JP2020510061A (ja) 2017-03-14 2020-04-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ピラゾロクロロフェニル化合物、組成物及びその使用方法
JP7228318B6 (ja) 2017-05-22 2023-03-10 エフ． ホフマン－ラ ロシュ アーゲー 処置用化合物及び組成物、並びにその使用方法
WO2018215389A1 (en) 2017-05-22 2018-11-29 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
WO2019139714A1 (en) 2018-01-15 2019-07-18 Genentech, Inc. Pyrazolopyrimidine compounds as jak inhibitors
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
WO2020257142A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof
AU2020297415A1 (en) 2019-06-18 2022-01-06 F. Hoffmann-La Roche Ag Pyrazolopyrimidine sulfone inhibitors of JAK kinases and uses thereof
CN114008050B (zh) 2019-06-18 2024-12-31 豪夫迈·罗氏有限公司 Jak激酶的吡唑并嘧啶芳基醚抑制剂及其用途
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61207400A (ja) * 1985-03-11 1986-09-13 Nippon Zoki Pharmaceut Co Ltd ヌクレオシド化合物の製造方法
US4751292A (en) 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US4859677A (en) 1987-04-17 1989-08-22 University Of Kansas Nucleoside analogues having antiviral activity
US5246931A (en) 1988-10-25 1993-09-21 Bristol-Myers Squibb Company Carbocyclic nucleoside analogs
US5688778A (en) 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
GB8916480D0 (en) 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5726302A (en) * 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5276151A (en) 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5470857A (en) 1990-09-14 1995-11-28 Marion Merrell Dow Inc. Carbocyclic nucleoside analogs useful as immunosuppressants
SE9003151D0 (sv) 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
TW374087B (en) 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
AU3086495A (en) * 1994-08-02 1996-03-04 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazoles
US5659023A (en) 1995-02-01 1997-08-19 Gilead Sciences, Inc. Nucleotide analogues
CA2244378A1 (en) 1996-01-23 1997-07-31 The Regents Of The University Of Michigan Modified benzimidazole nucleosides as antiviral agents

Also Published As

Publication number Publication date
EP1052264A2 (en) 2000-11-15
AR028991A1 (es) 2003-06-04
DE60018833D1 (de) 2005-04-28
US6271370B1 (en) 2001-08-07
KR100403900B1 (ko) 2003-11-01
EP1052264B1 (en) 2005-03-23
ZA200002263B (en) 2001-12-24
CA2307951A1 (en) 2000-11-11
AU3401100A (en) 2000-11-16
CN1275575A (zh) 2000-12-06
PL340109A1 (en) 2000-11-20
JP2001011092A (ja) 2001-01-16
YU25500A (sh) 2003-08-29
EP1052264A3 (en) 2001-06-13
RU2200738C2 (ru) 2003-03-20
HU0001843D0 (en) 2000-07-28
TR200001340A2 (tr) 2000-12-21
HUP0001843A2 (hu) 2001-06-28
ID25992A (id) 2000-11-16
CZ20001710A3 (cs) 2001-09-12
HUP0001843A3 (en) 2001-09-28
IN186850B (enEXAMPLES) 2001-11-24
IL136027A0 (en) 2001-05-20
MXPA00004532A (es) 2002-03-08
KR20010069193A (ko) 2001-07-23
BR0002089A (pt) 2001-01-02

Similar Documents

Publication Publication Date Title
ATE291582T1 (de) Verfahren zur synthese von nukleosidanaloga
EP1066308A4 (en) IMPROVED METHODS OF SYNTHESIS OF OLIGONUCLEOTIDES
ATE272613T1 (de) Verfahren zur synthese von cox-2 inhibitoren
EP1427743A4 (en) SYNTHESIS OF PYRAZOLOPYRIMIDINES
ATE388132T1 (de) Verfahren zur hydroformylierung von olefinen
DK0757684T3 (da) Fremgangsmåde til diastereoselektiv syntese af nucleosidanaloger
ATE369201T1 (de) Verfahren zur reinigung von synthesegas
DE59608364D1 (de) Verfahren zur selektiven Synthese von Silylalkyldisulfiden
ATE499153T1 (de) Verfahren zur vorhydrolyse von biomasse
DE60012979D1 (de) Verfahren zur selektiven dimerisierung von isobuten
DE69911195D1 (de) Verfahren zur direktoxidation von olefinen zu olefinoxiden
DE50002724D1 (de) Verfahren zur querstromfiltration
EP0979233A4 (en) Method for solution phase synthesis of oligonucleotides
DE60327356D1 (de) Verfahren zur synthese von metallnanoteilchen
EP1246833A4 (en) IMPROVED SYNTHESIS OF SULFUR OLIGONUCLEOTIDES
ATE437486T1 (de) Verfahren zur konfiguration von physischen kanälen
DE60012910D1 (de) Verfahren zur trennung von olefinen von gesättigten kohlenwasserstoffen
ATE326443T1 (de) Verfahren zur stereoselektiven synthese zyklischer aminosäuren
DE60201384D1 (de) Verfahren zur Synthese von Harnstoff
DE69824366D1 (de) Verfahren zur Synthese von Alkylpolyglucosiden
DE69817550D1 (de) Verfahren zur sprachsynthese
DE60010753D1 (de) Verfahren zur reinigung von lactamen
DE60117687D1 (de) Verfahren zur synthese von pfropfpolymeren
DE59900737D1 (de) Verfahren zur Synthese von Feststoffen
DE69232830D1 (de) Verfahren zur Synthese von D(+)-Biotin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties